Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

July 23, 2026

Study Completion Date

July 23, 2026

Conditions
Solid Tumors
Interventions
DRUG

Olaparib

Oral tablet

BIOLOGICAL

Pembrolizumab

Intravenous infusion

Trial Locations (135)

1079

Riga East Clinical University Hospital ( Site 2103), Riga

1930

Vaal Triangle Oncology Centre ( Site 1905), Vereeniging

2148

Blacktown Hospital ( Site 2202), Blacktown

2193

Wits Clinical Research ( Site 1906), Parktown-Johannesburg

3168

Monash Medical Centre ( Site 2205), Clayton

3414

Liepaja Regional Hospital ( Site 2101), Liepāja

4091

The Oncology Centre ( Site 1904), Durban

4215

Tasman Oncology Research Pty Ltd ( Site 2203), Southport

5417

Daugavpils Regional Hospital ( Site 2104), Daugavpils

6009

Linear Clinical Research Ltd ( Site 2206), Nedlands

7700

Cancercare Rondebosch Oncology ( Site 1901), Rondebosch

9301

Universitas Annex National Hospital ( Site 1902), Bloemfontein

10002

Zhytomyr Regional Oncology Center ( Site 1710), Zhytomyr

11776

New York Cancer and Blood Specialists-Research Department ( Site 0080), Port Jefferson Station

12203

Charite-Universitaetsmedizin Berlin-Campus Benjamin Franklin ( Site 0902), Berlin

13605

Seoul National University Bundang Hospital ( Site 2403), Seongnam-si

15036

Oncosalud ( Site 3200), Lima

15038

Instituto Nacional de Enfermedades Neoplasicas ( Site 3201), Lima

15082

Hospital Nacional Arzobispo Loayza ( Site 3208), Lima

15088

Clinica San Gabriel ( Site 3202), Lima

15102

Hospital Nacional Cayetano Heredia ( Site 3203), Lima

18009

Cherkasy Regional Oncology Dispensary ( Site 1702), Cherkasy

20162

ASST Grande Ospedale Metropolitano Niguarda ( Site 0700), Milan

21029

Podillya Regional Center of Oncology ( Site 1708), Vinnytsia

22030

Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1500), Edirne

22031

Inova Schar Cancer Institute ( Site 0008), Fairfax

25011

Kirovograd Regional oncology Dispensary ( Site 1716), Kropyvnytsky

25030

CHU Jean Minjoz ( Site 0606), Besançon

28007

Hospital General Universitario Gregorio Maranon ( Site 1300), Madrid

28223

Hospital Quiron de Madrid ( Site 1301), Pozuelo de Alarcón

29009

Khmelnitskiy Regional Onkology Dispensary ( Site 1705), Khmelnitskiy

30060

Northwest Georgia Oncology Centers PC ( Site 0047), Marietta

30322

Winship Cancer Institute of Emory University ( Site 0057), Atlanta

30501

Northeast Georgia Medical Center ( Site 0026), Gainesville

32608

University of Florida ( Site 0078), Gainesville

34098

Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1504), Istanbul

34298

Institut du Cancer de Montpellier ( Site 0610), Montpellier

34722

Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi ( Site 1505), Istanbul

35040

Ege Universitesi Tip Fakultesi Tulay Aktas Onkoloji Hastanesi ( Site 1501), Izmir

35233

The Kirklin Clinic ( Site 0086), Birmingham

37178

Preparaciones Oncologicas ( Site 3102), León

40207

Norton Cancer Institute - St. Matthews ( Site 0024), Louisville

41124

Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0703), Modena

42080

Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 1510), Konya

44106

University Hospitals Cleveland Medical Center ( Site 0016), Cleveland

44280

Inonu Universitesi Medical Fakultesi ( Site 1506), Malatya

49102

Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 1700), Dnipro

50937

Universitaetsklinik Koeln ( Site 0903), Cologne

53100

Azienda Ospedaliera Universitaria Senese ( Site 0704), Siena

61070

Communal non profit enterprise Regional Clinical Oncology Center ( Site 1704), Kharkiv

64460

Unidad Biomedica Avanzada Monterrey S. A. ( Site 3108), Monterrey

66278

Centro Medico Zambrano Hellion ( Site 3105), San Pedro Garza García

68017

Fundacion Cardiovascular de Colombia ( Site 2907), Piedecuesta

69035

Medical center of the Limited Liability Company Yulis ( Site 1714), Zaporizhzhia

72530

Clinica Integral Internacional de Oncologia S. de R.L. de C.V. ( Site 3107), Puebla City

73104

The University of Oklahoma Health Sciences Center ( Site 0050), Oklahoma City

75235

Parkland Health & Hospital System ( Site 0091), Dallas

75390

University of Texas, Southwestern Medical Center ( Site 0004), Dallas

76000

Hospital H+ Queretaro ( Site 3104), Querétaro City

76001

Hemato Oncologos S.A. ( Site 2910), Santiago de Cali

76018

"Communal Non-Commercial Enterprise Prykarpatski Clinical On-Department for daily treated patient (", Ivano-Frankivsk

76038

Centre Henri Becquerel ( Site 0607), Rouen

77030

University of Texas-MD Anderson Cancer Center ( Site 0087), Houston

80131

Istituto Nazionale Tumori Fondazione Pascale ( Site 0705), Napoli

80631

Banner MD Anderson Cancer Center ( Site 0092), Greeley

81377

Universitaetsklinik der Ludwig-Maximilians-Universitaet Muenchen ( Site 0906), Munich

84119

Utah Cancer Specialists ( Site 0038), West Valley City

85234

Banner MD Anderson Cancer Center ( Site 0049), Gilbert

85925

CHD Vendee ( Site 0604), La Roche-sur-Yon

89440

Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 3101), Madero

94115

San Francisco Oncology Associates ( Site 0085), San Francisco

94158

University of California San Francisco ( Site 0015), San Francisco

94800

Institut Gustave Roussy ( Site 0602), Villejuif

95817

UC Davis Comprehensive Cancer Center ( Site 0039), Sacramento

98405

Northwest Medical Specialties, PLLC ( Site 0007), Tacoma

200542

S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103), Craiova

300239

Policlinica Oncomed SRL ( Site 1104), Timișoara

400015

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1101), Cluj-Napoca

400641

Medisprof ( Site 1102), Cluj-Napoca

510007

Spitalul Judetean de Urgenta Alba Iulia ( Site 1107), Alba Iulia

760032

Fundacion Valle del Lili ( Site 2909), Santiago de Cali

3109601

Rambam Health Care Campus-Oncology Division ( Site 0801), Haifa

4428164

Meir Medical Center ( Site 0804), Kfar Saba

4941492

Rabin Medical Center ( Site 0806), Petah Tikva

5262000

Chaim Sheba Medical Center ( Site 0800), Ramat Gan

6423906

Sourasky Medical Center ( Site 0805), Tel Aviv

9112001

Hadassah Ein Kerem Medical Center ( Site 0802), Jerusalem

07901

Atlantic Health System ( Site 0046), Summit

C1121ABE

Fundacion CIDEA ( Site 2704), Ciudad de Buenos Aires

C1280AEB

Hospital Britanico de Buenos Aires ( Site 2705), Ciudad de Buenos Aires

C1426ABP

Centro Medico Dra De Salvo ( Site 2702), Buenos Aires

C1431FWO

CEMIC ( Site 2701), Buenos Aires

F5300COE

Centro Oncologico Riojano Integral ( Site 2703), La Rioja

V5Z 4E6

BC Cancer-Vancouver Center ( Site 0203), Vancouver

E1C 6Z8

Moncton Hospital - Horizon Health Network ( Site 0206), Moncton

H2X 1R9

Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0201), Montreal

050030

Fundación Colombiana de Cancerología Clínica Vida ( Site 2902), Medellín

080020

Clinica de la Costa S.A.S. ( Site 2900), Barranquilla

01010

Oncologika S.A. ( Site 3003), Guatemala City

01015

Grupo Angeles SA ( Site 3004), Guatemala City

Sanatorio Nuestra Senora del Pilar ( Site 3006), Guatemala City

01016

Medi-K Cayala ( Site 3005), Guatemala City

09002

Centro Medico Integral De Cancerología (CEMIC) ( Site 3002), Quetzaltenango

464-8681

Aichi Cancer Center Hospital ( Site 2504), Nagoya

277-8577

National Cancer Center Hospital East ( Site 2500), Kashiwa

060-8648

Hokkaido University Hospital ( Site 2502), Sapporo

812-8582

Kyushu University Hospital ( Site 2506), Fukuoka

700-8558

Okayama University Hospital ( Site 2505), Okayama

104-0045

National Cancer Center Hospital ( Site 2501), Tokyo

135-8550

Japanese Foundation for Cancer Research ( Site 2503), Tokyo

LV-1002

P. Stradina Clinical University Hospital ( Site 2102), Riga

06100

CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 3103), Mexico City

Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1502), Ankara

04001

Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 3206), Arequipa

07021

Hospital Nacional Daniel Alcides Carrion ( Site 3207), Bellavista

08003

Hospital Nacional Adolfo Guevara Velasco ( Site 3205), Cuzco

02-781

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warsaw

80-214

Uniwersyteckie Centrum Kliniczne ( Site 1809), Gdansk

00674

Hematology and Oncology Institute ( Site 0504), Manatí

00717

Ad-Vance Medical Research LLC ( Site 0505), Ponce

00935

Pan American Center for Oncology Trials LLC ( Site 0501), Rio Piedras

00927

FDI Clinical Research ( Site 0500), San Juan

0181

Mary Potter Oncology Centre, Little Company of Mary Hospital ( Site 1900), Pretoria

03080

Seoul National University Hospital ( Site 2402), Seoul

03722

Severance Hospital Yonsei University Health System ( Site 2400), Seoul

06351

Samsung Medical Center ( Site 2401), Seoul

08036

Hospital Clinic i Provincial ( Site 1302), Barcelona

221 85

Skanes Universitetssjukhus Lund. ( Site 2001), Lund

171 76

Karolinska Universitetssjukhuset Solna ( Site 2000), Solna

751 85

Akademiska Sjukhuset ( Site 2002), Uppsala

01250

Baskent University Adana Training Hospital ( Site 1509), Adana

06500

Gazi Universitesi Tip Fakultesi ( Site 1507), Ankara

06800

Ankara Sehir Hastanesi ( Site 1508), Ankara

07070

Akdeniz Universitesi Tıp Fakultesi ( Site 1503), Antalya

04050

Medical Centre Consilium Medical ( Site 1712), Kyiv

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04123366 - Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) | Biotech Hunter | Biotech Hunter